Search arXiv⌕ Search

arXiv · 0705.4429

A successive sub-grouping method for multiple sequence alignments analysis

Abstract

A novel approach to protein multiple sequence alignment is discussed: substantially this method counterparts with substitution matrix based methods (like Blosum or PAM based methods), and implies a more deterministic approach to chemical/physical sub-grouping of amino acids . Amino acids (aa) are divided into sub-groups with successive derivations, that result in a clustering based on the considered property. The properties can be user defined or chosen between default schemes, like those used in the analysis described here. Starting from an initial set of the 20 naturally occurring amino acids, they are successively divided on the basis of their polarity/hydrophobic index, with increasing resolution up to four level of subdivision. Other schemes of subdivision are possible: in this thesis work it was employed also a scheme based on physical/structural properties (solvent exposure, lateral chain mobility and secondary structure tendency), that have been compared to the chemical scheme with testing purposes. In the method described in this chapter, the total score for each position in the alignment accounts for different degree of similarity between amino acids. The scoring value result form the contribution of each level of selectivity for every individual property considered. Simply the method (called M_Al) analyse the n sequence alignment position per position and assigns a score which have contributes by aa identity plus a composed valuation of the chemical or of the structural affinity between the n aligned amino acids. This method has been implemented in a series of programs written in python language; these programs have been tested in some biological cases, with benchmark purposes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Stefano Marino. 2007-06-07. A successive sub-grouping method for multiple sequence alignments analysis. https://arxiv.org/abs/0705.4429

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

Comparison of anomaly detection and supervised learning for acute myeloid leukemia blast identification: A proof-of-concept study

Background. Flow cytometry is the established standard for identifying leukemic blast populations in AML, but relies predominantly on subjective, time-consuming manual gating. Machine learning approaches are being explored to support automated blast detection, yet the relative performance of anomaly detection versus supervised classification remains incompletely characterized. Methods. We compared six computational approaches for blast identification: four anomaly detection algorithms (Isolation Forest, One-Class SVM, Local Outlier Factor, Half-Space Trees), a supervised Random Forest classifier, and an unsupervised UMAP-HDBSCAN clustering approach. The models were developed on the BLAST110 cohort (110 samples) using nested cross-validation with patient-level grouping, and externally validated on two independent LAIP29 samples spanning high (about 41%) and low (about 1%) blast prevalence. Results. Random Forest achieved the strongest external validation performance (F1 = 0.965 diagnostic sample; F1 = 0.587 follow-up sample). Anomaly detection methods showed weaker, more variable performance, with substantial further decline at low blast prevalence (F1 as low as 0.0006); One-Class SVM performed best among anomaly detectors (F1 = 0.731, diagnostic sample). Several models showed a marked drop in performance between cross-validation and external validation. UMAP-HDBSCAN clustering failed to separate blast and non-blast populations into distinct clusters. Conclusions. Supervised classification substantially outperformed the anomaly detection and unsupervised clustering approaches evaluated here, contrasting with prior work favoring anomaly detection for AML blast identification. This divergence may reflect differences in anomaly detection design; label-efficient approaches may still hold practical value where labeled data collection is limited.

q-bio.OT↗

FISH Omics Format: a standard enabling FAIR chromatin tracing data sharing across repositories

In recent years, multiplexed Fluorescence In Situ Hybridization (FISH) or FISH-omics methods have rapidly expanded, enabling the quantification of chromatin organization in single cells, often in conjunction with measurements of RNAs and proteins. These approaches have deepened our understanding of how 3D chromosome architecture relates to transcriptional activity and cell states in health and disease. Despite these advances, results from Chromatin Tracing FISH-omics experiments remain challenging to share, reuse, and analyze due to the absence of standardized data exchange specifications. Building on the release of microscopy metadata standards, we introduce the FISH Omics Format-Chromatin Tracing (FOF-CT), a community-developed standard for processed results from diverse imaging modalities. We describe the FOF-CT file format and present a curated collection of datasets deposited in the 4D Nucleome Data Portal and the OME Image Data Resource (IDR). We also highlight their potential for reuse, integration, and modeling by outlining example analysis pipelines and illustrating biological insights enabled by standardized, FAIR-compliant Chromatin Tracing datasets. FOF-CT natively represents both ball-and-stick and volumetric Chromatin Tracing data, unifying the two modalities within a single, modular table-based architecture (FOF-bas-CT and FOF-vol-CT, respectively).

q-bio.OT↗

Drug-Associated Rhabdomyolysis in the FDA Adverse Event Reporting System (FAERS): A Disproportionality Analysis

This study aimed to systematically identify and quantify risks for drug-induced rhabdomyolysis (DIR) using real-world data and to propose an evidence-based risk mitigation framework. We conducted a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database from Q1 2005 to Q1 2025. A two-stage analysis involved initial signal detection using the Reporting Odds Ratio (ROR), followed by a LASSO-optimized multivariate logistic regression to calculate adjusted odds ratios (aORs) for 54 target drugs while controlling for confounders. Our analysis confirmed potent DIR risks for known agents, such as gemfibrozil (aOR 173.67) and statins (lovastatin aOR 97.20, simvastatin aOR 85.12). Crucially, we identified strong, novel risk signals for drugs currently lacking warnings, most notably levetiracetam (aOR 11.02) and donepezil (aOR 8.90). A significant "labeling gap" was quantified: 61.1% of drugs with a statistically significant DIR risk lack a corresponding warning in U.S. drug labels. We subsequently developed a three-tiered risk stratification model. The proposed framework provides a data-driven foundation for developing tiered clinical decision support systems, enhancing prescribing safety, and guiding future regulatory action to bridge the identified evidence-to-labeling gap.

q-bio.OT↗